Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albendazole · 1 trial · 1 indication
AUC (0-t) was evaluated using the trapezoid rule.
AUC (0-inf) was evaluated using the trapezoid rule.
Cmax was depicted from plasma concentration of Albendazole.
| Arm | Type | Description |
|---|---|---|
| Albendazole tablet (Aqua Based) | EXPERIMENTAL | Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment. |
| Albendazole tablet (Alcohol Based) | ACTIVE_COMPARATOR | Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment. |
| Name | Type | Description |
|---|---|---|
| Albendazole | DRUG | Albendazole tablets 400 mg |
Inclusion Criteria: 1. Male aged from 18 years up to 40 years (inclusive). 2. Body mass index within the range of 19-24kg/m\^2. 3. Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination. 4. Negati...
Albendazole is used for helminthiasis, a condition caused by parasitic worm infections. It is being developed as a small molecule treatment for this infectious disease. The drug is currently in clinical development and is not yet approved for this use.
Albendazole is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy for treating helminthiasis.
Albendazole is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still undergoing clinical evaluation for the treatment of helminthiasis.
Albendazole has one completed Phase 1 clinical trial, identified as NCT01755637. This was a bioequivalence study of Albendazole 400 mg tablets conducted in a Chinese population. The trial enrolled 56 healthy male volunteers and was active-controlled, though it was not double-blinded.
Albendazole is the drug name provided, and no alternative names have been mentioned. It is a small molecule being studied for helminthiasis. If you are looking for other names, they have not been specified in the available information.